{
  "pmcid": "10481925",
  "sha256": "0305db21d300fb47361a29388a9eb8f8ce1a0a5856bf026edc450f7723eed0e5",
  "timestamp_utc": "2025-11-09T23:07:12.072299+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 9.29547619047619,
    "reading_ease": 47.12035714285716,
    "word_count": 273
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial of Indocyanine Green Fluorescence Imaging in Minimally Invasive Rectal Cancer Surgery"
      },
      "Trial_Design": {
        "score": 2,
        "evidence": "open-label, phase III randomised controlled trial"
      },
      "Participants": {
        "score": 2,
        "evidence": "Patients with stage 0–III rectal carcinoma less than 12 cm from the anal verge, scheduled for minimally invasive sphincter-preserving surgery"
      },
      "Intervention": {
        "score": 2,
        "evidence": "randomised 1:1 to receive ICG-FI (ICG+ group) or no ICG-FI (ICG− group)"
      },
      "Objective": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was the anastomotic leakage rate (grade A+B+C) within 30 days post-surgery"
      },
      "Randomisation_Allocation": {
        "score": 1,
        "evidence": "Randomisation was computerised, and allocation was not concealed"
      },
      "Blinding": {
        "score": 0,
        "evidence": "Neither patients nor clinicians were blinded"
      },
      "Number_Randomised": {
        "score": 2,
        "evidence": "Between December 2018 and February 2021, 850 patients were randomised (422 to ICG+ and 417 to ICG−)"
      },
      "Number_Analysed": {
        "score": 2,
        "evidence": "The modified intention-to-treat analysis included 839 patients"
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "The anastomotic leakage rate was 7.6% in the ICG+ group versus 11.8% in the ICG− group (relative risk 0.645; 95% CI 0.422–0.987; p = 0.041)"
      },
      "Harms": {
        "score": 1,
        "evidence": "No adverse events related to ICG were reported"
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "Trial registration: jRCTs-CRB3180007, UMIN-CTR000030240"
      },
      "Funding": {
        "score": 1,
        "evidence": "Funding: Stryker Japan K.K."
      }
    },
    "total_score": 20,
    "max_score": 25
  }
}